专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2010270151A Thiadiazole dioxide and thiadiazole oxide as cxc-chemokine receptor ligand and cc-chemokine receptor ligand 审中-公开
标题翻译：噻唑二氧化物和噻唑烷氧化物作为CXC-CHEMOKINE受体配体和CC-CHEMOKINE受体配体
公开(公告)号：JP2010270151A
公开(公告)日：2010-12-02
申请号：JP2010197184
申请日：2010-09-02
申请人： Pharmacopeia Inc , Schering Corp , シェーリングコーポレイションSchering Corporation , ファーマコピアインコーポレーテッドPharmacopeia, Inc
发明人： TAVERAS ARTHUR G , CHAO JIANHUA , BIJU PURAKKATTLE J , YU YOUNONG , FINE JAY S , HIPKIN WILLIAM , AKI CYNTHIA J , MERRITT J ROBERT , LI GE , BALDWIN JOHN J , LAI GAIFA , WU MINGLANG , HECKER EVAN A
IPC分类号： C07D285/10 , A61K31/433 , A61K31/4439 , A61P1/04 , A61P1/16 , A61P1/18 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P11/08 , A61P13/12 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P19/10 , A61P25/04 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/04 , A61P33/06 , A61P35/00 , A61P37/06 , A61P43/00 , C07D417/02 , C07D417/12 , C07D417/14
CPC分类号： C07D285/10 , C07D417/02 , C07D417/12 , C07D417/14
摘要： PROBLEM TO BE SOLVED: To provide CXC-chemokine receptor ligands and CC-chemokine receptor ligands. SOLUTION: Novel compounds of formula (IA) are provided. As examples of the group containing the substituent A, heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino are cited. As examples of groups containing the substituent B, aryl and heteroaryl are cited. Methods for treating chemokine-mediated diseases (e.g., cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain) are also disclosed. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：提供CXC趋化因子受体配体和CC趋化因子受体配体。解决方案：提供新的式（IA）化合物。作为含有取代基A的基团的实例，可以举出杂芳基，芳基，杂环烷基，环烷基，芳基，炔基，烯基，氨基烷基，烷基或氨基。作为含有取代基B的基团的实例，可列举芳基和杂芳基。用于治疗趋化因子介导的疾病（例如癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化症，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，急性疼痛，急性和慢性炎性疼痛和神经性疼痛）的方法也是披露。版权所有（C）2011，JPO＆INPIT

2. 发明专利

JP2010168406A Pyrazolopyrimidine as cyclin dependent kinase inhibitor 审中-公开
标题翻译：作为CYCLIN依赖性激酶抑制剂的吡唑并嘧啶
公开(公告)号：JP2010168406A
公开(公告)日：2010-08-05
申请号：JP2010112695
申请日：2010-05-14
申请人： Pharmacopeia Inc , Schering Corp , シェーリングコーポレイションSchering Corporation , ファーマコピアインコーポレーテッドPharmacopeia, Inc
发明人： GUZI TIMOTHY J , PARUCH KAMIL , DWYER MICHAEL P , DOLL RONALD J , GIRIJAVALLABHAN VIYYOOR MOOPIL , DILLARD LAWRENCE W , TRAN VINH D , HE ZHEN MIN , JAMES RAY ANTHONY , PARK HAENGSOON
IPC分类号： C07D487/04 , A61K31/519 , A61K45/00 , A61P25/00 , A61P35/00 , A61P35/02 , A61P43/00
CPC分类号： C07D487/04 , A61K31/519 , A61K31/52 , A61K31/704 , A61K31/7072 , A61K45/06 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide compounds useful for treatment, prevention, or amelioration of diseases and trouble associated with the CDKs.
SOLUTION: The invention provides in its many embodiments, a new class of pyrazolo[1,5-α]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供可用于治疗，预防或改善与CDK有关的疾病和麻烦的化合物。解决方案：本发明在其许多实施方案中提供了一类新的作为细胞周期蛋白依赖性激酶抑制剂的吡唑并[1,5-α]嘧啶化合物，制备这些化合物的方法，含有一种或多种这类化合物的药物组合物，方法制备包含一种或多种这样的化合物的药物制剂，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。版权所有（C）2010，JPO＆INPIT

3. 发明申请

US20150105354A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS 审中-公开
公开(公告)号：US20150105354A1
公开(公告)日：2015-04-16
申请号：US14575418
申请日：2014-12-18
申请人： Merck Sharp & Dohme Corp. , Pharmacopeia, LLC
发明人： Zhaoning Zhu , Brian McKittrick , Zhong-Yue Sun , Yuanzan C. Ye , Johannes H. Voigt , Corey Strickland , Elizabeth M. Smith , Andrew W. Stamford , William J. Greenlee , Robert D. Mazzola, JR. , John Caldwell , Jared N. Cumming , Lingyan Wang , Yusheng Wu , Ulrich Iserloh , Tao Guo , Thuy X.H. Le , Kurt W. Saionz , Suresh D. Babu , Rachael C. Hunter
IPC分类号： C07D233/88 , C07D401/04 , A61K31/4439 , C07D405/06 , A61K31/4178 , C07D401/06 , A61K31/454 , C07D407/06 , C07D403/06 , A61K31/5377 , C07D235/02 , A61K31/4184 , A61K31/655 , C07D405/14 , C07D401/14 , A61K31/4545 , A61K31/4725 , A61K45/06 , A61K31/4168
CPC分类号： C07D233/88 , A61K31/4168 , A61K31/4178 , A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/5377 , A61K31/655 , A61K45/06 , C07D233/46 , C07D233/70 , C07D235/02 , C07D239/22 , C07D239/70 , C07D271/07 , C07D273/00 , C07D295/15 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/06 , C07D405/10 , C07D405/14 , C07D407/06 , C07D409/04 , C07D409/06 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/06 , Y02A50/411
摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.

4. 发明申请

US20140128361A1 CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT 有权
标题翻译：具有苄基取代基的环酰胺BACE-1抑制剂
公开(公告)号：US20140128361A1
公开(公告)日：2014-05-08
申请号：US14148703
申请日：2014-01-06
申请人： Pharmacopeia Drug Discovery, Inc. , Merck Sharp & Dohme Corp.
发明人： Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voight , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey H. Lowrie , Kurt W. Salonz , Suresh D. Babu
IPC分类号： C07D243/08 , C07D233/32 , C07D205/04
CPC分类号： C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, whereinR1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译：公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中R1是R是-C（O）-N（R27）（R28），或其余的变量如说明书中所定义。还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。还公开了治疗认知或神经变性疾病的药物组合物和方法，其包含式I化合物与除式I以外的分泌抑制剂抑制剂，HMG-CoA还原酶抑制剂，γ-分泌酶抑制剂，非 - 甾族抗炎药，N-甲基-D-天冬氨酸受体拮抗剂，胆碱酯酶抑制剂或抗淀粉样蛋白抗体。

5. 发明申请

US20040171614A1 Novel gamma secretase inhibitors 审中-公开
标题翻译：新型γ分泌酶抑制剂
公开(公告)号：US20040171614A1
公开(公告)日：2004-09-02
申请号：US10663042
申请日：2003-09-16
申请人： Schering-Plough Corporation , Pharmacopeia, Inc.
发明人： Dmitri A. Pissarnitski , Hubert B. Josien , Elizabeth M. Smith , John W. Clader , Theodros Asberom , Tao Guo , Douglas W. Hobbs
IPC分类号： A61K031/5377 , A61K031/496 , A61K031/4545 , A61K031/454 , C07D413/02 , C07D43/02
CPC分类号： C07D401/14 , C07D207/08 , C07D211/96 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D451/06 , C07D471/04 , C07D471/10 , C07D491/10
摘要： This invention discloses novel gamma secretase inhibitors of the formula: 1 wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, nullXC(O)Y, alkylene-XC(O)Y, cycloalkylene-X-C(O)nullY, nullCHnullXnullC(O)nullNR3nullY or nullCHnullXnullC(O)nullY, wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.
摘要翻译：本发明公开了下式的新型γ分泌酶抑制剂：其中：R 1是取代的芳基或取代的杂芳基; R 2是R 1基团，烷基，-XC（O）Y，亚烷基-XC（O）Y，亚环烷基-XC（O）-Y，-CH-XC（O）-NR 3 -Y或-CH-XC（O）-Y，其中X和Y如本文所定义; 每个R 3和每个R 3A独立地是H或烷基; R 11是芳基，杂芳基，烷基，环烷基，芳基烷基，芳基环烷基，杂芳基烷基，杂芳基环烷基，芳基杂环烷基或烷氧基烷基。还公开了使用一种或多种本发明化合物治疗阿尔茨海默病的方法。

6. 发明申请

US20030228624A1 Molecular docking methods for assessing complementarity of combinatorial libraries to biotargets 审中-公开
标题翻译：用于评估组合文库对生物靶的互补性的分子对接方法
公开(公告)号：US20030228624A1
公开(公告)日：2003-12-11
申请号：US10320752
申请日：2002-12-16
申请人： Pharmacopeia, Inc.
发明人： David J. Diller , Kenneth M. Merz JR.
IPC分类号： G01N033/53 , G06G007/48 , G06G007/58
CPC分类号： C07K1/047
摘要： A high-throughput molecular docking facility is presented for screening combinatorial libraries to identity binding ligands and ultimately pharmaceutical compounds. The facility employs a pre-coking conformational search to generate multiple solution conformations of a ligand. The molecular docking facility includes: generating a binding site image of the target molecule, the binding site image to atoms in at least one solution conformation of the multiple solution conformations of the ligand to obtain at least one ligand postion relative to the target molecule in a ligand-target molecule complex formation; and optimizing the at least one ligand position while allowing translation, orientation and rotatable bonds of the ligand to vary, and while holding the target molecule fixed. Docking results are clustered using as a metric the rms deviation between the core of two docked molecules. A library is rated as to complementarity to the target molecule according to the relative number of ligands in the top cluster.
摘要翻译：提出了一种高通量分子对接设备，用于筛选组合文库以鉴定结合配体和最终的药物化合物。该设施采用预焦化构象搜索以产生配体的多个溶液构象。分子对接设备包括：产生靶分子的结合位点图像，以配体的多个溶液构象的至少一个溶液构象中的原子的结合位点图像，以获得相对于靶分子的至少一个配体位点配体 - 靶分子复合体形成; 并优化至少一个配体位置，同时允许配体的翻译，取向和可旋转键发生变化，同时保持靶分子固定。对接结果使用两个对接分子的核心之间的均方根偏差作为度量进行聚类。根据顶部簇中的配体的相对数量，文库被评定为与靶分子的互补性。

7. 发明申请

US20030215871A1 Chemically inert molecular tags 审中-公开
标题翻译：化学惰性分子标签
公开(公告)号：US20030215871A1
公开(公告)日：2003-11-20
申请号：US10137139
申请日：2002-05-01
申请人： PHARMACOPEIA, INC.
发明人： John J. Baldwin , Roland E. Dolle III , Lawrence W. Dillard , Joan Guo
IPC分类号： G01N033/53 , C07C069/52 , G01N033/543
CPC分类号： C40B70/00 , C07B2200/11 , C07C69/92 , C07C245/14
摘要： A method for identifying a solid support in combinatorial synthesis or determining the structure of a compound in combinatorial synthesis. The method involves attaching, detaching and identifying at least one tag by detaching the tag from the solid support and reacting the detached tag with a fluoroalkanoyl acid or its alcohol-reactive equivalent. A preferred linker/tag is of formula 1 in which R1 is C13 to C33 alkane or ether.
摘要翻译：用于在组合合成中鉴定固体支持物或确定组合合成中化合物的结构的方法。该方法包括通过从固体支持物上分离标签并使分离的标签与氟烷酰基酸或其醇反应性等价物反应来附接，分离和鉴定至少一个标签。优选的接头/标签是其中R 1为C 13至C 33烷烃或醚的通式。

8. 发明专利

JP2011074088A Pyrazolopyrimidine as cyclin dependent kinase inhibitor 审中-公开
标题翻译：作为CYCLIN依赖性激酶抑制剂的吡唑并嘧啶
公开(公告)号：JP2011074088A
公开(公告)日：2011-04-14
申请号：JP2011005344
申请日：2011-01-13
申请人： Pharmacopeia Inc , Schering Corp , シェーリングコーポレイションSchering Corporation , ファーマコピア, インコーポレイテッド
发明人： GUZI TIMOTHY J , PARUCH KAMIL , DWYER MICHAEL P , DOLL RONALD J , GIRIJAVALLABHAN VIYYOOR MOOPIL , KNUTSON CHAD , MCKITTRICK BRIAN , DILLARD LAWRENCE W , TRAN VINH D , HE ZHEN MIN , JAMES RAY ANTHONY , PARK HAENGSOON
IPC分类号： C07D487/04 , A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/08 , A61P13/12 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/00 , A61P25/00 , A61P25/04 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/10 , A61P31/12 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00
CPC分类号： C07D487/04
摘要： PROBLEM TO BE SOLVED: To provide new compounds, formulations, treatment and therapy for treating diseases and disorders associated with CDK.
SOLUTION: In its many embodiments, there are provided a new class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供新的化合物，制剂，治疗和治疗用于治疗与CDK相关的疾病和病症。解决方案：在其许多实施方案中，提供了一类新的作为细胞周期依赖性激酶抑制剂的吡唑并[1,5-a]嘧啶化合物，制备这些化合物的方法，含有一种或多种这类化合物的药物组合物，方法制备包含一种或多种这样的化合物的药物制剂，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。版权所有（C）2011，JPO＆INPIT

9. 发明专利

JP2010215675A Pyrazolopyrimidine derivative as cyclin dependent kinase inhibitor 审中-公开
标题翻译：作为CYCLIN依赖性激酶抑制剂的吡唑并嘧啶衍生物
公开(公告)号：JP2010215675A
公开(公告)日：2010-09-30
申请号：JP2010157338
申请日：2010-07-09
申请人： Pharmacopeia Drug Discovery Inc , Schering Corp , シェーリングコーポレイションSchering Corporation , ファーマコペイアドラッグディスカバリー, インコーポレイテッド
发明人： GUZI TIMOTHY J , PARUCH KAMIL , DWYER MICHAEL P , DOLL RONALD J , GIRIJAVALLABHAN VIYYOOR MOOPIL , MALLAMS ALAN , ALVAREZ CARMEN S , KEERTIKAR KARTIK M , RIVERA JOCELYN , CHAN TIN-YAU , MADISON VINCENT , FISCHMANN THIERRY O , DILLARD LAWRENCE W , TRAN VINH D , HE ZHEN MIN , JAMES RAY ANTHONY , PARK HAENGSOON , PARADKAR VIDYADHAR M , HOBBS DOUGLAS WALSH
IPC分类号： C07D487/04 , A61K31/437 , A61K31/444 , A61K31/495 , A61K31/519 , A61K31/5355 , A61K41/00 , A61K45/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D453/02
CPC分类号： C07D487/04 , A61K31/495
摘要： PROBLEM TO BE SOLVED: To provide cyclin dependent kinase inhibitors. SOLUTION: The invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing one or more kind of such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供细胞周期蛋白依赖性激酶抑制剂。解决方案：本发明提供了一类新颖的吡唑并[1,5-a]嘧啶化合物作为细胞周期蛋白依赖性激酶的抑制剂，制备一种或多种这类化合物的方法，含有一种或多种这类化合物的药物组合物，方法制备包含一种或多种这样的化合物的药物制剂，以及使用这些化合物或药物组合物治疗，预防，抑制或改善与CDK相关的一种或多种疾病的方法。版权所有（C）2010，JPO＆INPIT

10. 发明专利

JP2010180234A Pyrazolopyrimidine as cyclin-dependent kinase inhibitor 审中-公开
标题翻译：作为CYCLIN依赖性激酶抑制剂的吡唑并嘧啶
公开(公告)号：JP2010180234A
公开(公告)日：2010-08-19
申请号：JP2010088210
申请日：2010-04-06
申请人： Pharmacopeia Inc , Schering Corp , シェーリングコーポレイションSchering Corporation , ファーマコピア, インコーポレイテッド
发明人： GUZI TIMOTHY J , PARUCH KAMIL , DWYER MICHAEL P , DOLL RONALD J , GIRIJAVALLABHAN VIYYOOR MOOPIL , MALLAMS ALAN , ALVAREZ CARMEN S , KEERTIKAR KARTIK M , RIVERA JOCELYN , CHAN TIN-YAU , MADISON VINCENT , FISCHMANN THIERRY O , DILLARD LAWRENCE W , TRAN VINH D , HE ZHEN MIN , JAMES RAY ANTHONY , PARK HAENGSOON , PARADKAR VIDYADHAR M , HOBBS DOUGLAS WALSH
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61K31/551 , A61K45/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D519/00
CPC分类号： C07D487/04
摘要： PROBLEM TO BE SOLVED: To provide a compound useful as a protein kinase inhibitor. SOLUTION: A new class of a pyrazolo[1,5-a]pyrimidine compound represented by the formula as an inhibitor of a cyclin-dependent kinase is provided in many embodiments. A method for preparing such a compound, a pharmacological composition comprising one or more such compounds, a method for preparing a pharmacological formulation comprising one or more such compounds, and a method for treating, preventing, inhibiting or ameliorating one or more diseases associated with a CDK using such a compound or such a pharmacological composition are also provided. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供可用作蛋白激酶抑制剂的化合物。解决方案：在许多实施方案中提供了一类新的由式表示的吡唑并[1,5-a]嘧啶化合物作为细胞周期蛋白依赖性激酶的抑制剂。一种制备这种化合物的方法，包含一种或多种这样的化合物的药物组合物，包含一种或多种这样的化合物的药物制剂的制备方法，以及治疗，预防，抑制或改善一种或多种与还提供使用这种化合物的CDK或这样的药物组合物。版权所有（C）2010，JPO＆INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式